Analysis of recurrence after the resection of pancreatic neuroendocrine tumors

Konstantinos Chouliaras, Naeem A. Newman, Mrinal Shukla, Katrina R. Swett, Edward A. Levine, Jonathan Sham, Gary N. Mann, Perry Shen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Objectives: Outcomes after recurrence of resected pancreatic neuroendocrine tumors (PNETs) are not well described. We aim to assess the rate and sites of recurrence, and its effect on clinical outcomes. Methods: Retrospective chart review of patients (n = 83) who underwent surgical resection of PNETs at 2 institutions. Patients were treated from September 2002 to July 2010. Results: There were 13 (16%) recurrences. The most common site of recurrence was the liver (9 patients, 9.6%). The most common treatment of recurrences was chemotherapy (5 patients, 36%). The 1-, 3-, and 5-year disease-free survival was 90.9%, 82.7%, and 72.5%, respectively. Median recurrence-free survival was 127 months. The median follow-up for all PNET patients was 25.8 months (range, 1-140 months). The 3-year survival was 97%. The median follow-up of patients after the diagnosis of a recurrence was 13.8 months. The overall survival for those with and without recurrence was 96.3% and 100%, respectively (P =.36). The age (P =.002) and lymph node ratio (P <.001) were predictors of recurrence on multivariate analysis. Conclusions: Age and lymph node ratio are significant predictors of recurrence after the resection of PNETs with hepatic metastases being the most common. Survival of patients with recurrence is not significantly different from patients without recurrence.

Original languageEnglish (US)
Pages (from-to)416-421
Number of pages6
JournalJournal of Surgical Oncology
Volume118
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Neuroendocrine Tumors
Recurrence
Survival
Lymph Nodes
Liver
Disease-Free Survival
Multivariate Analysis

Keywords

  • liver metastases
  • lymph node ratio (LNR)
  • predictors of survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Chouliaras, K., Newman, N. A., Shukla, M., Swett, K. R., Levine, E. A., Sham, J., ... Shen, P. (2018). Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 118(3), 416-421. https://doi.org/10.1002/jso.25146

Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. / Chouliaras, Konstantinos; Newman, Naeem A.; Shukla, Mrinal; Swett, Katrina R.; Levine, Edward A.; Sham, Jonathan; Mann, Gary N.; Shen, Perry.

In: Journal of Surgical Oncology, Vol. 118, No. 3, 01.09.2018, p. 416-421.

Research output: Contribution to journalArticle

Chouliaras, K, Newman, NA, Shukla, M, Swett, KR, Levine, EA, Sham, J, Mann, GN & Shen, P 2018, 'Analysis of recurrence after the resection of pancreatic neuroendocrine tumors', Journal of Surgical Oncology, vol. 118, no. 3, pp. 416-421. https://doi.org/10.1002/jso.25146
Chouliaras, Konstantinos ; Newman, Naeem A. ; Shukla, Mrinal ; Swett, Katrina R. ; Levine, Edward A. ; Sham, Jonathan ; Mann, Gary N. ; Shen, Perry. / Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. In: Journal of Surgical Oncology. 2018 ; Vol. 118, No. 3. pp. 416-421.
@article{605ba5e706844a36b5006ecfcb74ee07,
title = "Analysis of recurrence after the resection of pancreatic neuroendocrine tumors",
abstract = "Background and Objectives: Outcomes after recurrence of resected pancreatic neuroendocrine tumors (PNETs) are not well described. We aim to assess the rate and sites of recurrence, and its effect on clinical outcomes. Methods: Retrospective chart review of patients (n = 83) who underwent surgical resection of PNETs at 2 institutions. Patients were treated from September 2002 to July 2010. Results: There were 13 (16{\%}) recurrences. The most common site of recurrence was the liver (9 patients, 9.6{\%}). The most common treatment of recurrences was chemotherapy (5 patients, 36{\%}). The 1-, 3-, and 5-year disease-free survival was 90.9{\%}, 82.7{\%}, and 72.5{\%}, respectively. Median recurrence-free survival was 127 months. The median follow-up for all PNET patients was 25.8 months (range, 1-140 months). The 3-year survival was 97{\%}. The median follow-up of patients after the diagnosis of a recurrence was 13.8 months. The overall survival for those with and without recurrence was 96.3{\%} and 100{\%}, respectively (P =.36). The age (P =.002) and lymph node ratio (P <.001) were predictors of recurrence on multivariate analysis. Conclusions: Age and lymph node ratio are significant predictors of recurrence after the resection of PNETs with hepatic metastases being the most common. Survival of patients with recurrence is not significantly different from patients without recurrence.",
keywords = "liver metastases, lymph node ratio (LNR), predictors of survival",
author = "Konstantinos Chouliaras and Newman, {Naeem A.} and Mrinal Shukla and Swett, {Katrina R.} and Levine, {Edward A.} and Jonathan Sham and Mann, {Gary N.} and Perry Shen",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/jso.25146",
language = "English (US)",
volume = "118",
pages = "416--421",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Analysis of recurrence after the resection of pancreatic neuroendocrine tumors

AU - Chouliaras, Konstantinos

AU - Newman, Naeem A.

AU - Shukla, Mrinal

AU - Swett, Katrina R.

AU - Levine, Edward A.

AU - Sham, Jonathan

AU - Mann, Gary N.

AU - Shen, Perry

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background and Objectives: Outcomes after recurrence of resected pancreatic neuroendocrine tumors (PNETs) are not well described. We aim to assess the rate and sites of recurrence, and its effect on clinical outcomes. Methods: Retrospective chart review of patients (n = 83) who underwent surgical resection of PNETs at 2 institutions. Patients were treated from September 2002 to July 2010. Results: There were 13 (16%) recurrences. The most common site of recurrence was the liver (9 patients, 9.6%). The most common treatment of recurrences was chemotherapy (5 patients, 36%). The 1-, 3-, and 5-year disease-free survival was 90.9%, 82.7%, and 72.5%, respectively. Median recurrence-free survival was 127 months. The median follow-up for all PNET patients was 25.8 months (range, 1-140 months). The 3-year survival was 97%. The median follow-up of patients after the diagnosis of a recurrence was 13.8 months. The overall survival for those with and without recurrence was 96.3% and 100%, respectively (P =.36). The age (P =.002) and lymph node ratio (P <.001) were predictors of recurrence on multivariate analysis. Conclusions: Age and lymph node ratio are significant predictors of recurrence after the resection of PNETs with hepatic metastases being the most common. Survival of patients with recurrence is not significantly different from patients without recurrence.

AB - Background and Objectives: Outcomes after recurrence of resected pancreatic neuroendocrine tumors (PNETs) are not well described. We aim to assess the rate and sites of recurrence, and its effect on clinical outcomes. Methods: Retrospective chart review of patients (n = 83) who underwent surgical resection of PNETs at 2 institutions. Patients were treated from September 2002 to July 2010. Results: There were 13 (16%) recurrences. The most common site of recurrence was the liver (9 patients, 9.6%). The most common treatment of recurrences was chemotherapy (5 patients, 36%). The 1-, 3-, and 5-year disease-free survival was 90.9%, 82.7%, and 72.5%, respectively. Median recurrence-free survival was 127 months. The median follow-up for all PNET patients was 25.8 months (range, 1-140 months). The 3-year survival was 97%. The median follow-up of patients after the diagnosis of a recurrence was 13.8 months. The overall survival for those with and without recurrence was 96.3% and 100%, respectively (P =.36). The age (P =.002) and lymph node ratio (P <.001) were predictors of recurrence on multivariate analysis. Conclusions: Age and lymph node ratio are significant predictors of recurrence after the resection of PNETs with hepatic metastases being the most common. Survival of patients with recurrence is not significantly different from patients without recurrence.

KW - liver metastases

KW - lymph node ratio (LNR)

KW - predictors of survival

UR - http://www.scopus.com/inward/record.url?scp=85053922265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053922265&partnerID=8YFLogxK

U2 - 10.1002/jso.25146

DO - 10.1002/jso.25146

M3 - Article

VL - 118

SP - 416

EP - 421

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -